Free Trial

Harmony Biosciences (HRMY) Stock Forecast & Price Target

$33.75
+0.43 (+1.29%)
(As of 07/12/2024 ET)

Harmony Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$41.67
23.46% Upside
High Forecast$59.00
Average Forecast$41.67
Low Forecast$27.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.67$40.63$40.63$62.89
Forecasted Upside23.46% Upside34.35% Upside34.02% Upside37.78% Upside
Get Harmony Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.

HRMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HRMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Harmony Biosciences Stock vs. The Competition

TypeHarmony BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside23.46% Upside994.26% Upside9.16% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/24/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$52.00 ➝ $52.00+66.72%
6/21/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Hoang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$48.00+66.61%
4/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$49.00+58.94%
2/27/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$42.00 ➝ $40.00+20.63%
1/9/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$25.00 ➝ $28.00-14.40%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Underperform$30.00-7.12%
11/1/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$26.00 ➝ $27.00+14.70%
10/16/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$72.00 ➝ $42.00+78.88%
9/7/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$59.00+61.03%
10/14/2022Janney Montgomery Scott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$57.00 ➝ $61.00+28.07%
10/14/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$57.00 ➝ $61.00+28.07%
8/3/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$62.00 ➝ $67.00+28.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:05 PM ET.

HRMY Forecast - Frequently Asked Questions

What is Harmony Biosciences' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Harmony Biosciences is $41.67, with a high forecast of $59.00 and a low forecast of $27.00.

Should I buy or sell Harmony Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HRMY shares.

Does Harmony Biosciences's stock price have much upside?

According to analysts, Harmony Biosciences's stock has a predicted upside of 37.53% based on their 12-month stock forecasts.

What analysts cover Harmony Biosciences?

Harmony Biosciences has been rated by research analysts at Citigroup, and Needham & Company LLC in the past 90 days.

Do Wall Street analysts like Harmony Biosciences more than its competitors?

Analysts like Harmony Biosciences less than other "medical" companies. The consensus rating score for Harmony Biosciences is 2.56 while the average consensus rating score for "medical" companies is 2.71. Learn more on how HRMY compares to other companies.


This page (NASDAQ:HRMY) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners